XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer.

Proc Natl Acad Sci U S A · 2022 · PMC8795568 · PMID 35064087

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

This affirmed a highly significant reduction in KRAS transcription following treatment with XP-524 ( Fig. 3 F ), which was also observed using MiaPaCa2 and ASPC1 cells ( Fig. 3 G and H ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.